2024 International Congress » Parkinson's Disease: Psychiatric Manifestations

Meeting: 2024 International Congress

Apathy in de novo Parkinson’s disease improves after the first years with dopaminergic treatment.

A. Castrioto, M. Anheim, E. Schmitt, S. Meoni, JL. Houeto, H. Klinger, D. Sourd, P. Pelissier, E. Lhommee, C. Tranchant, JP. Azulay, F. Durif, E. Moro, V. Fraix, S. Thobois, P. Krack (Grenoble, France)

Assessing the Accuracy of Clinical features, CSF Dopamine Metabolites, and Striatal Binding Ratios for the Likelihood of Depression Over 10-year Follow Up in the PPMI Cohort.

J. Li, A. Basu, C. Song, I. Bedoy, J. Ruiz Tejeda, S. Nguyen, R. Rajmohan, N. Phielipp (Irvine, USA)

Characterizing Dopaminergic Correlates of Depression in Parkinson’s Disease: The PPMI Cohort

C. Song, A. Basu, I. Bedoy, J. Li, J. Ruiz Tejeda, S. Nguyen, R. Rajmohan, N. Phielipp (Irvine, USA)

Comorbidity of schizophrenia and Parkinson’s disease: a clinical case report

M. Khommyatov, M. Samushiya, I. Smolentseva, S. Kryzhanovskiy (Moscow, Russian Federation)

Dopamine agonist use and psychotic symptoms in patients with Parkinson’s disease.

D. Ortiz-Zacarias, S. Castillo-Torres, M. Cansino-Torres, J. Trejo-Ayala, B. Chávez-Luevanos, I. Estrada-Bellmann (Monterrey, Mexico)

Dopamine Dysregulation in Parkinson’s Disease and Substance Use: Therapeutic Use and Compulsive Behaviors Thin Line

J. Hall, R. Islam, D. Nolasco, B. Carr (GAINESVILLE, USA)

Exploring the Root of Cognitive Decline in People Living with Parkinson’s Disease: An Analysis of MoCA Scores, Neuropsychiatric Symptoms, and Patient-Reported Outcomes

K. Sánchez-Ramírez, S. Arechavala-Lopez, D. Romero-Terán, A. Hernández-Medrano, M. Medina-Pérez, A. Cervantes-Arriaga, M. Rodríguez-Violante (CULIACAN, Mexico)

Gender Disparities in Depressive Symptoms among Hispanic Parkinson’s Disease Patients: A Cross-Sectional Study

C. Rodriguez-Alarcon, D. Piana-Castillo, G. Faggioni-Sanchez, D. Bustamante-Mieles, C. Cevallos-Velasco, M. Barreiro-Guillén, R. Santibanez-Vasquez (Guayaquil, Ecuador)

Gender-related Cognitive Disparities in Hispanic Patients with Parkinson’s Disease: A Cross-Sectional Study

D. Piana-Castillo, C. Rodriguez-Alarcon, G. Faggioni-Sanchez, D. Bustamante-Mieles, C. Cevallos-Velasco, M. Barreiro-Guillén, R. Santibanez-Vasquez (Guayaquil, Ecuador)

Listening to the Insight: The Underdiagnosis of Depression in People Living with Parkinson’s Disease

G. Rivera-Monroy, RJ. Baños-Betancourt, K. Velázquez-Román, CF. álvarez-Hernández, AL. Guerra-Anzaldo, WF. Moguel-Cardín, A. Domínguez-García, MF. Medina-Pérez, JC. Delgado-Uriarte, NP. Moreno-Aldama, A. Uribe-León, MC. Unda-Mcfarlane, AJ. Hernández-Medrano, A. Cervantes-Arriaga, M. Rodríguez-Violante (Mexico City, Mexico)

Modeling the Role of Parkinson’s Disease-Specific Factors in Depression and Anxiety: Findings from MEX-PD Cohort

P. Reyes-Pérez, D. Martínez, I. Estrada-Bellmann, C. Guerra-Galicia, N. Gandarilla-Martínez, E. Morelos Figaredo, K. Salinas-Barboza, Y. Matuk-Pérez, A. Lazaro-Figueroa, M. Rentería, S. Alcauter-Solorzano, A. Ruiz-Contreras, A. Medina-Rivera (Queretaro, Mexico)

Neuropathological Synergy in Cauda Equina Syndrome, Parkinson’s Disease, And Depression: Breaking the Dysphoric Cycle

R. Grace, L. Velez, R. Islam, B. Carr (Gainesville, USA)

Neurophysiological Underpinnings of Apathy in Parkinson’s Disease Versus Depressive Disorders: A Comparative Study

D. Nolasco, A. Sohel, B. Carr (Gainesville, USA)

Obsessive-Compulsive Disorder Prevalence in Parkinson’s Disease Caregivers

F. Hojjatipour, M. Salari (tehran, Islamic Republic of Iran)

Outcomes in Patients with Parkinsonism Treated for Acute Agitation with Intravenous Benzodiazepines Compared to Parenteral Antipsychotics While Inpatient

A. Kundrick, C. Piccinin, J. Yu, P. Clark, S. Shaffer, O. Hogue, C. Sonneborn, B. Sokola, S. Sperling, H. Fernandez, B. Walter (Cleveland, USA)

Pharmacokinetic Intersections in Geriatric Neuropharmacology: A Parkinson’s Disease Case Study with Concomitant Refractory Major Depressive Disorder

D. Nolasco, L. Schmidt, B. Carr (Gainesville, USA)

Psychotic features in patients with Parkinson’s disease

S. Frikha, O. Ben Othmen, M. Ben Mahmoud, S. Fray, H. Jamoussi, M. Fredj, N. Ben Ali (Tunis, Tunisia)

Reduced Thalamic Nuclei Volume May Contribute to Anxiety in Parkinson’s Disease: a 7-Tesla MRI Study

G. Carey, M. Kuijf, S. Michielse, A. Wolters, K. Dujardin, A. Leentjens (Lille, France)

Resting state EEG source analysis identifies distinct neural signature associated with impulse control disorders in PD

E. Iglesias-Camacho, FJ. Gómez Campos, P. Franco Rosado, L. Garrote Espina, AM. Castellano-Gerrero, M. San Eufrasio, C. Perez-Calvo, L. Muñoz-Delgado, S. Jesús, D. Macías-García, E. Ojeda-Lepe, A. Adarmes-Gómez, F. Carrillo, JF. Martín-Rodriguez, P. Mir (Seville, Spain)

Safety of Pimavanserin for Parkinson’s Disease Psychosis: Exploratory Analysis of Sedation and Sleep Data From Clinical Studies

A. Berrio, L. Chrones, V. Abler, R. Hauser (San Diego, USA)